ORSERDUTM (ELACESTRANT)

Publications

  Journal of Clinical Oncology (2022): Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

VIEW NOW

Journal of Clinical Oncology (2021): Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

VIEW NOW

Presentations

Nothing found.

ELZONRIS® (TAGRAXOFUSP)

Publications

Journal of Clinical Oncology (2022): Long-Term Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

VIEW NOW

  New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

VIEW NOW

Presentations

Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. ASH 2021.

Poster


A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH 2020.

Poster


Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms. ASH 2019.

Poster


Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2019.

Oral Presentation


Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. ASH 2019.

Poster


CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp. ACR 2019.

Poster

 


SL-801

Nothing found.

SL-701

Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. AACR 2012.

Abstract | Poster


A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. AACR 2012.

Abstract


Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011.

Abstract